logo-loader
viewApricus Biosciences Inc

Apricus holds US rights for Vitaros as sells the rest to Ferring

Apricus Biosciences Inc. shares opened 18.5% higher on Thursday at $3.29 after confirming overnight it had completed the sale to Ferring International Center SA of Apricus’ ex-US assets and rights related to Vitaros

shutterstock_155356055.jpg
Vitaros non-US assets sold to Ferring

Apricus Biosciences Inc. (NASDAQ:APRI) shares opened 18.5% higher on Thursday at $3.29 after confirming overnight it had completed the sale to Ferring International Center SA, a privately listed firm, of Apricus’ ex-US assets and rights related to Vitaros.

Vitaros is Apricus’ on-demand topical cream indicated for the treatment of patients with erectile dysfunction.

Ferring is Apricus’ commercial partner for Vitaros in Latin America and certain parts of Europe and Asia.

Apricus will retain its Vitaros rights in the US and it remains on track to re-submit the Vitaros New Drug Application to the Food and Drug Administration in the third quarter of 2017.

However, the opening share price was diluted from pre-market activity which saw the stock up as much as 26%.

Quick facts: Apricus Biosciences Inc

Price: - -

NASDAQ:APRI
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'Significant' cobalt demand growth expected over next decade with market...

Roskill's Ying Lu says a combination of expansions, re-starts, recycling and new projects will be required if Cobalt supply is to meet demand over the next decade. She's forecasting significant cobalt demand growth over the next decade with the market expected to roughly double in size. 

6 hours, 27 minutes ago

2 min read